Suven Life Sciences gets nod to raise Rs 400 crore on rights basis
24th Jun 2022

Suven Life Sciences has received approval to raise Rs 400 crore through issuance and allotment of equity shares having face value of Rs 1 each on rights basis and on such terms (as decided by the Board or a duly constituted committee of the Board, at a later date) to the eligible equity shareholders of the Company, as on the record date (to be notified subsequently), subject to receipt of regulatory/ statutory approvals, in accordance with the applicable laws including the provisions of the Securities and Exchange Board of India. The board of directors of the Company at their meeting held on June 24, 2022 approved the same.

Suven Life Sciences provides wide range of Drug Discovery and Development Support Services (DDDSS) to global Pharma and Biotech companies. Suven has state-of-art facilities with highly qualified & experienced team of scientists.